NewAmsterdam Pharma resurrects Amgen's old CETP drug with plans to jump into PhIII this year
Eli Lilly thought it found the “holy grail” a decade ago with a CETP inhibitor that lowered bad cholesterol and raised …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
